Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma
In conclusion, ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.PMID:38451242 | DOI:10.1093/ejendo/lvae022 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Juliane Lippert Gabrielle Smith Silke Appenzeller Laura-Sophie Landwehr Alessandro Prete Sonja Steinhauer Miriam Asia Hanna Urlaub Yasir S Elhassan Stefan Kircher Wiebke Arlt Martin Fassnacht Barbara Altieri Cristina L Ronchi Source Type: research
Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma
In conclusion, ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.PMID:38451242 | DOI:10.1093/ejendo/lvae022 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Juliane Lippert Gabrielle Smith Silke Appenzeller Laura-Sophie Landwehr Alessandro Prete Sonja Steinhauer Miriam Asia Hanna Urlaub Yasir S Elhassan Stefan Kircher Wiebke Arlt Martin Fassnacht Barbara Altieri Cristina L Ronchi Source Type: research
Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma
In conclusion, ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.PMID:38451242 | DOI:10.1093/ejendo/lvae022 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Juliane Lippert Gabrielle Smith Silke Appenzeller Laura-Sophie Landwehr Alessandro Prete Sonja Steinhauer Miriam Asia Hanna Urlaub Yasir S Elhassan Stefan Kircher Wiebke Arlt Martin Fassnacht Barbara Altieri Cristina L Ronchi Source Type: research
Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma
In conclusion, ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.PMID:38451242 | DOI:10.1093/ejendo/lvae022 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - March 7, 2024 Category: Endocrinology Authors: Juliane Lippert Gabrielle Smith Silke Appenzeller Laura-Sophie Landwehr Alessandro Prete Sonja Steinhauer Miriam Asia Hanna Urlaub Yasir S Elhassan Stefan Kircher Wiebke Arlt Martin Fassnacht Barbara Altieri Cristina L Ronchi Source Type: research
The MQRG score: a novel prognostic tool for adrenocortical carcinoma patients based on mitochondrial quality
ConclusionsMultilayer alterations in MQRGs are associated with patient prognosis and immune cell infiltration characteristics. This comprehensive analysis of MQRGs can contribute to a deeper understanding of potential differences in ACC patients' tumor microenvironment. This can influence clinical decision-making and advanced prognosis prediction, thereby offering new insights into personalized treatments in ACC. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 5, 2024 Category: Endocrinology Source Type: research
"Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma"
J Clin Endocrinol Metab. 2024 Feb 28:dgae109. doi: 10.1210/clinem/dgae109. Online ahead of print.ABSTRACTAdrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis in advanced stages. While therapies targeting the checkpoint molecules programmed cell death 1 (PD-1), its ligand PD-L1 and the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized treatment in many cancers, the results in ACC were heterogeneous. Their expression in ACC has not been systematically studied and might explain the variable response to checkpoint inhibitors. The expression of PD-1, PD-L1 and CTLA-4 was exami...
Source: The Journal of Clinical Endocrinology and Metabolism - February 28, 2024 Category: Endocrinology Authors: Laura-Sophie Landwehr Barbara Altieri Iuliu Sbiera Hanna Remde Stefan Kircher Julie Olabe Silviu Sbiera Matthias Kroiss Martin Fassnacht Source Type: research
Cancers, Vol. 16, Pages 900: The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
ya Shreenivas
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of different malignancies. However, their efficacy in advanced adrenocortical carcinoma (ACC) remains uncertain. Thus, we conducted a systematic review and meta-analysis to summarize the efficacy and tolerability of ICIs in patients with advanced ACC. We searched PubMed, Scopus, and CENTRAL for studies that used ICIs in ACC. Studies with more than five patients were included in the meta-analysis of the objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and grade 3/4 adverse...
Source: Cancers - February 23, 2024 Category: Cancer & Oncology Authors: Obada Ababneh Alina Ghazou Mohmmad Alawajneh Saleh Alhaj Mohammad Abdullah Bani-Hani Nasr Alrabadi Aditya Shreenivas Tags: Systematic Review Source Type: research
Abstract No. 228 Clinical Outcomes of Imaging-Guided Localized Treatments in Patients with Adrenocortical Carcinoma: A Retrospective Study
To assess the safety and efficacy of image-guided locoregional therapies (IGLTs) in patients with metastatic or recurrent adrenocortical carcinoma (ACC). (Source: Journal of Vascular and Interventional Radiology : JVIR)
Source: Journal of Vascular and Interventional Radiology : JVIR - February 21, 2024 Category: Radiology Authors: K. Pal, B. Chahla, V. Balderrama-Brondani, S. Gupta, M. Campbell, M. Habra, R. Sheth Source Type: research
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches
Oncologist. 2024 Feb 21:oyae029. doi: 10.1093/oncolo/oyae029. Online ahead of print.ABSTRACTAdrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Divya Chukkalore Kira MacDougall Viraj Master Mehmet Asim Bilen Bassel Nazha Source Type: research
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches
Oncologist. 2024 Feb 21:oyae029. doi: 10.1093/oncolo/oyae029. Online ahead of print.ABSTRACTAdrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Divya Chukkalore Kira MacDougall Viraj Master Mehmet Asim Bilen Bassel Nazha Source Type: research
Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma
AbstractPurpose of ReviewTo provide a comprehensive overview of the current understanding and developments in the treatment options for adrenocortical carcinoma (ACC), focusing on the strategies utilized for advanced disease.Recent FindingsResearch has delved into the genomic landscape of ACC, revealing potential targets for therapy. Despite the failure of inhibitors aimed at the insulin like growth factor 1(IGF-1) receptor, other approaches, including vascular endothelial growth factor receptor (VEFGR) tyrosine kinase inhibitors and immune checkpoint inhibitors, are being investigated. There are also ongoing trials of com...
Source: Current Oncology Reports - February 21, 2024 Category: Cancer & Oncology Source Type: research
Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma
ConclusionIn treatment-na ïve ACC patients, the quantitative PET parameter failed to predict OS, but presence of metastases detected by [18F]FDG PET/CT and Ki-67 index were independently associated with shorter OS. Therefore, a simple visual PET-based read-out is of prognostic value at initial diagnosis, while time-consuming PET-based quantification can be omitted. (Source: Endocrine)
Source: Endocrine - February 21, 2024 Category: Endocrinology Source Type: research
